The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance
Michael Kilian,Mirco J. Friedrich,Kevin Hai-Ning Lu,David Vonhören,Selina Jansky,Julius Michel,Anna Keib,Saskia Stange,Nicolaj Hackert,Niklas Kehl,Markus Hahn,Antje Habel,Stefanie Jung,Kristine Jähne,Felix Sahm,Johannes Betge,Adelheid Cerwenka,Frank Westermann,Peter Dreger,Marc S. Raab,Nadja M. Meindl-Beinker,Matthias Ebert,Lukas Bunse,Carsten Müller-Tidow,Michael Schmitt,Michael Platten
DOI: https://doi.org/10.1126/sciimmunol.adj7970
IF: 30.63
2024-05-05
Science Immunology
Abstract:Understanding the mechanisms that regulate T cell immunity is critical for the development of effective therapies for diseases associated with T cell dysfunction, including autoimmune diseases, chronic infections, and cancer. Co-inhibitory "checkpoint molecules," such as programmed cell death protein-1, balance excessive or prolonged immune activation by T cell–intrinsic signaling. Here, by screening for mediators of natural killer (NK) cell recognition on T cells, we identified the immunoglobulin superfamily ligand B7H6 to be highly expressed by activated T cells, including patient-infused CD19-targeting chimeric antigen receptor (CAR) T cells. Unlike other checkpoint molecules, B7H6 mediated NKp30-dependent recognition and subsequent cytolysis of activated T cells by NK cells. B7H6 + T cells were prevalent in the tissue and blood of several diseases, and their abundance in tumor tissue positively correlated with clinical response in a cohort of patients with immune checkpoint inhibitor–treated esophageal cancer. In humanized mouse models, NK cell surveillance via B7H6 limited the persistence and antitumor activity of CAR T cells, and its genetic deletion enhanced T cell proliferation and persistence. Together, we provide evidence of B7H6 protein expression by activated T cells and suggest the B7H6-NKp30 axis as a therapeutically actionable NK cell–dependent immune checkpoint that regulates human T cell function.
immunology